JP2024536859A5 - - Google Patents

Info

Publication number
JP2024536859A5
JP2024536859A5 JP2024518776A JP2024518776A JP2024536859A5 JP 2024536859 A5 JP2024536859 A5 JP 2024536859A5 JP 2024518776 A JP2024518776 A JP 2024518776A JP 2024518776 A JP2024518776 A JP 2024518776A JP 2024536859 A5 JP2024536859 A5 JP 2024536859A5
Authority
JP
Japan
Prior art keywords
chimeric receptor
cancer
receptor polypeptide
genetically modified
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024518776A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024536859A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/077103 external-priority patent/WO2023049933A1/en
Publication of JP2024536859A publication Critical patent/JP2024536859A/ja
Publication of JP2024536859A5 publication Critical patent/JP2024536859A5/ja
Pending legal-status Critical Current

Links

JP2024518776A 2021-09-27 2022-09-27 解糖経路からグルコース代謝産物を再誘導するトランス代謝分子と組み合わせたキメラ受容体ポリペプチド及びその治療的使用 Pending JP2024536859A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163248629P 2021-09-27 2021-09-27
US63/248,629 2021-09-27
US202263399324P 2022-08-19 2022-08-19
US63/399,324 2022-08-19
PCT/US2022/077103 WO2023049933A1 (en) 2021-09-27 2022-09-27 Chimeric receptor polypeptides in combination with trans metabolism molecules that re-direct glucose metabolites out of the glycolysis pathway and therapeutic uses thereof

Publications (2)

Publication Number Publication Date
JP2024536859A JP2024536859A (ja) 2024-10-08
JP2024536859A5 true JP2024536859A5 (enExample) 2025-10-06

Family

ID=83996759

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024518776A Pending JP2024536859A (ja) 2021-09-27 2022-09-27 解糖経路からグルコース代謝産物を再誘導するトランス代謝分子と組み合わせたキメラ受容体ポリペプチド及びその治療的使用

Country Status (9)

Country Link
US (1) US20240390495A1 (enExample)
EP (1) EP4408982A1 (enExample)
JP (1) JP2024536859A (enExample)
KR (1) KR20240069799A (enExample)
AU (1) AU2022349103A1 (enExample)
CA (1) CA3232833A1 (enExample)
IL (1) IL311712A (enExample)
MX (1) MX2024004009A (enExample)
WO (1) WO2023049933A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020037066A1 (en) * 2018-08-14 2020-02-20 Unum Therapeutics Inc. Chimeric antigen receptor polypeptides in combination with trans metabolism molecules modulating krebs cycle and therapeutic uses thereof
WO2024040207A1 (en) 2022-08-19 2024-02-22 Sotio Biotech Inc. Genetically engineered natural killer (nk) cells with chimeric receptor polypeptides in combination with trans metabolism molecules and therapeutic uses thereof
US20260053924A1 (en) 2022-08-19 2026-02-26 Sotio Biotech Inc. Genetically engineered immune cells with chimeric receptor polypeptides in combination with multiple trans metabolism molecules and therapeutic uses thereof
WO2024215987A1 (en) 2023-04-14 2024-10-17 Sotio Biotech Inc. IMMUNE CELLS FOR TREATING CANCER IN COMBINATION WITH IL-15/IL-15Rα CONJUGATES
EP4694916A1 (en) 2023-04-14 2026-02-18 SOTIO Biotech Inc. Engineered immune cells for treating cancer in combination with il-2/il-15 receptor ?? agonists
WO2025038646A1 (en) * 2023-08-14 2025-02-20 Intellia Therapeutics, Inc. Cd70 car-t compositions and methods for cell-based therapy

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4650764A (en) 1983-04-12 1987-03-17 Wisconsin Alumni Research Foundation Helper cell
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US4980289A (en) 1987-04-27 1990-12-25 Wisconsin Alumni Research Foundation Promoter deficient retroviral vector
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
US5124263A (en) 1989-01-12 1992-06-23 Wisconsin Alumni Research Foundation Recombination resistant retroviral helper cell and products produced thereby
EP0832980B1 (en) 1989-01-23 2002-06-19 Chiron Corporation Recombinant therapies for infection and hyperproliferative disorders
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
EP1001032A3 (en) 1989-08-18 2005-02-23 Chiron Corporation Recombinant retroviruses delivering vector constructs to target cells
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
ATE237694T1 (de) 1991-08-20 2003-05-15 Us Gov Health & Human Serv Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
WO1993010218A1 (en) 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
GB9125623D0 (en) 1991-12-02 1992-01-29 Dynal As Cell modification
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
EP0650370A4 (en) 1992-06-08 1995-11-22 Univ California METHODS AND COMPOSITIONS TARGETED ON SPECIFIC TISSUES.
EP0644946A4 (en) 1992-06-10 1997-03-12 Us Health VECTOR PARTICLES RESISTANT TO INACTIVATION BY HUMAN SERUM.
GB2269175A (en) 1992-07-31 1994-02-02 Imperial College Retroviral vectors
EP0673431A1 (en) 1992-12-03 1995-09-27 Genzyme Corporation Gene therapy for cystic fibrosis
EP0705344B8 (en) 1993-06-24 2006-05-10 Advec Inc. Adenovirus vectors for gene therapy
AU7477394A (en) 1993-07-30 1995-03-27 University Of Medicine And Dentistry Of New Jersey Efficient gene transfer into primary lymphocytes
DE69435223D1 (de) 1993-10-25 2009-09-03 Canji Inc Rekombinanter Adenoviren-Vektor und Verfahren zur Verwendung
US5756910A (en) 1996-08-28 1998-05-26 Burgett, Inc. Method and apparatus for actuating solenoids in a player piano
EP0968284B1 (en) 1996-11-20 2006-12-13 Introgen Therapeutics, Inc. An improved method for the production and purification of adenoviral vectors
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
AU2474700A (en) 1998-12-01 2000-06-19 Genentech Inc. Secreted amd transmembrane polypeptides and nucleic acids encoding the same
JP2002541845A (ja) 1999-04-16 2002-12-10 セルテック セラピューティックス リミテッド 合成膜貫通成分
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
DK3178835T3 (da) 2009-02-03 2019-06-24 Amunix Pharmaceuticals Inc Forlængede rekombinante polypeptider og sammensætninger omfattende samme
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
KR20140060541A (ko) 2011-09-16 2014-05-20 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 암을 치료하기 위한 rna 조작된 t 세포
KR102308597B1 (ko) 2013-10-17 2021-10-01 내셔널 유니버시티 오브 싱가포르 다중 종양에 대항하여 항체-의존성 세포 세포독성을 촉발시키는 키메라 수용체
WO2016040441A1 (en) 2014-09-09 2016-03-17 Unum Therapeutics Chimeric receptors and uses thereof in immune therapy
EP3430036A4 (en) 2016-03-18 2019-08-14 Unum Therapeutics MODIFIED CHIMERIC RECEPTORS AND USES IN IMMUNOTHERAPY
CN110494162A (zh) 2017-01-30 2019-11-22 优努姆治疗公司 改良的抗体-偶联t细胞受体构建体及其治疗用途
WO2020010110A1 (en) 2018-07-03 2020-01-09 Unum Therapeutics Inc. Chimeric receptors in combination with trans metabolism molecules enhancing glucose import and therapeutic uses thereof
WO2020037066A1 (en) * 2018-08-14 2020-02-20 Unum Therapeutics Inc. Chimeric antigen receptor polypeptides in combination with trans metabolism molecules modulating krebs cycle and therapeutic uses thereof
AU2020245437A1 (en) * 2019-03-22 2021-09-30 Sumitomo Pharma Oncology, Inc. Compositions comprising PKM2 modulators and methods of treatment using the same

Similar Documents

Publication Publication Date Title
JP7106610B2 (ja) 導入遺伝子の遺伝子タグおよびその使用方法
Zhang et al. Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity
Pockley et al. NK cell-based therapeutics for lung cancer
JP2021534740A5 (enExample)
RU2747733C1 (ru) Терапевтические средства
JP2022169543A (ja) 改善された養子t細胞療法
JP2021536265A5 (enExample)
KR102483822B1 (ko) 태그된 키메라 이펙터 분자 및 그의 리셉터
JP2022550899A5 (enExample)
RU2700765C2 (ru) Способ и композиции для клеточной иммунотерапии
Hillerdal et al. Systemic treatment with CAR-engineered T cells against PSCA delays subcutaneous tumor growth and prolongs survival of mice
US20190023764A1 (en) Car having replicated binding motifs in a co-stimulatory domain
US20190321404A1 (en) Novel chimeric antigen receptor and use thereof
JP2021505131A5 (enExample)
JP2021529559A5 (enExample)
JP2019531328A5 (enExample)
JP2023549098A5 (enExample)
Fellermeier et al. Advancing targeted co-stimulation with antibody-fusion proteins by introducing TNF superfamily members in a single-chain format
US12187776B2 (en) Pooling signaling and costimulatory domains in B7H6 chimeric antigen receptor
WO2018045034A1 (en) Chimeric antigen receptors having gitr intracellular domain as co-stimulatory domain
JP2024515920A5 (enExample)
CN117683139A (zh) 组成型嵌合细胞因子受体及表达其的免疫细胞及应用
CN117202921A (zh) 用于多种免疫细胞的单链和多链合成抗原受体
RU2024129913A (ru) Клетки, имеющие нацеленный на солидную опухоль каркас, и их применение
NZ772146A (en) Chimeric antigen receptor polypeptides in combination with trans metabolism molecules modulating krebs cycle and therapeutic uses thereof